Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Norwich Expands Capabilities for Phase I-III Clinical Trials

By Pharmaceutical Processing | February 2, 2012

norwichncs

Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I – III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.

 “Utilizing proven technologies and this new, modern clinical facility, NCS is now able to offer functional expertise and therapeutic experience with reliability that will create cost and time efficiency for customers,” stated Dr. Saral Thangam, MD, PhD, managing director of Norwich Clinical Services. “We are proud to be opening this new clinical trial facility with full regulatory approval from the Drugs Controller General of India as an indication of our unequivocal adherence to GCP, GLP, CFR part 11 and other applicable regulatory requirements.”

The 72-bed, 16,500 square foot facility has been successfully audited by the Drugs Controller General of India and contains separate areas for subject screening and blood draws, an on-site pharmacy and a fully equipped intensive care unit. In conjunction with this new facility opening, Norwich Clinical Services is also conducting additional clinical programs within a separate FDA and EMA-approved research facility. Studies conducted at this 86-bed facility have been submitted to prominent health agencies including FDA, EMA, TPD, MHRA and DCGI.

 “Our customers’ needs are rapidly evolving for contract pharmaceutical services and we understand that Norwich capabilities must also evolve to include one comprehensive solution for all stages of the product lifecycle,” said Terry Novak, president of Norwich Pharmaceuticals, the parent company for Norwich Clinical Services. “Combining the clinical trial capabilities of these two research facilities will meet a specific need for Norwich customers seeking budget efficiency and schedule adherence from the early stages of development through study-end reconciliation.”

 

INTERPHEX 2012 Booth No. 1245

 

 

Related Articles Read More >

Q-Control Family
Q&A: Introducing PSG Biotech its role in biopharmaceutical flow control and monitoring technologies
Stäubli
Stäubli highlights pharmaceutical packaging robots at Pack Expo 
downtown
INTERPHEX Wrap-Up
INTERPHEX Minute: Day 3
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE